- Home
- ZIP vs AURA Comparison
ZIP vs AURA Comparison
Compare ZIP & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | AURA |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.3M | 396.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZIP | AURA |
|---|---|---|
| Price | $5.31 | $6.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.88 | ★ $20.33 |
| AVG Volume (30 Days) | ★ 806.3K | 200.9K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $448,299,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $4.35 |
| 52 Week High | $8.56 | $9.14 |
Technical Indicators
Market Signals| Indicator | ZIP | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 66.19 | 60.80 |
| Support Level | $5.12 | $5.89 |
| Resistance Level | $4.84 | $6.53 |
| Average True Range (ATR) | 0.29 | 0.33 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 86.05 | 86.21 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.